Aragen Bioscience Announces Ground Breaking on State Of the Art Research Facility
News Jan 29, 2016
Dedicated to the testing and characterization of novel therapeutics and vaccines, the new research space will add 15,000 sq.ft. to Aragen’s existing laboratories and will double capacity for diverse efficacy studies. Such studies are critical to the development of products that improve the diagnosis, treatment and prevention of disease including for example, fibrotic and infectious disease, oncology and other immunologically related indications.
“This project demonstrates Aragen’s commitment to future growth and meeting the needs of our clients for value-added services. The new facility not only expands general capacity but is constructed for high technical performance and tight environmental control including provision of BSL-2 studies. We look forward to seeing the building progress and its opening later this year,” commented Dr. Malavika Ghosh, Aragen’s Vice President of Preclinical Services.
The facility, which is designed for AAALAC accreditation and GLP compliance, is scheduled to be functional in the second quarter of 2016.
Shire, Microsoft and EURORDIS Form Global Commission to Accelerate Rare Disease DiagnosisNews
The alliance aims to shorten the often multi-year journey that patients and families endure before being diagnosed with a rare disease.READ MORE
Breast Cancer: How Advanced Imaging Technologies Will Help Avoid Unnecessary BiopsiesNews
Scientists have combined an advanced method of diffusion-weighted MR imaging with intelligent image analysis methods to detect malignant changes in tissues. This method may help avoid many control biopsies following suspicious findings from mammography screening.READ MORE
Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast CancerNews
A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer.READ MORE